

Evaluation of complications after ERCP using a short type double balloon endoscope in patients with altered gastrointestinal anatomy: a single-center retrospective study of 1,576 procedures

Journal:	<i>Journal of Gastroenterology and Hepatology</i>
Manuscript ID	JGH-02622-2019.R1
Manuscript Type:	Original Article - Endoscopy
Date Submitted by the Author:	23-Feb-2020
Complete List of Authors:	<p>Tokuhara, Mitsuo; Kansai Medical University Hirakata Hospital, Third Department of Internal Medicine, Division of Gastroenterology and Hepatology</p> <p>Shimatani, Masaaki; Kansai Medical University Hirakata Hospital, Third Department of Internal Medicine, Division of Gastroenterology and Hepatology</p> <p>Mitsuyama, Toshiyuki; Kansai Medical University Hirakata Hospital, Third Department of Internal Medicine, Division of Gastroenterology and Hepatology</p> <p>Masuda, Masataka; Kansai Medical University Hirakata Hospital, Third Department of Internal Medicine, Division of Gastroenterology and Hepatology</p> <p>Ito, Takashi; Kansai Medical University Hirakata Hospital, Third Department of Internal Medicine, Division of Gastroenterology and Hepatology</p> <p>Miyamoto, Sachi; Kansai Medical University Hirakata Hospital, Third Department of Internal Medicine, Division of Gastroenterology and Hepatology</p> <p>Fukata, Norimasa; Kansai Medical University Hirakata Hospital, Third Department of Internal Medicine, Division of Gastroenterology and Hepatology</p> <p>Miyoshi, Hideaki; Kansai Medical University Hirakata Hospital, Third Department of Internal Medicine, Division of Gastroenterology and Hepatology</p> <p>Ikeura, Tsukasa; Kansai Medical University Hirakata Hospital, Third Department of Internal Medicine, Division of Gastroenterology and Hepatology</p> <p>Takaoka, Makoto; Kansai Medical University Hirakata Hospital, Third Department of Internal Medicine, Division of Gastroenterology and Hepatology</p> <p>Kouda, Katsuyasu; Kansai Medical University Hirakata Hospital,</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Department of Hygiene and Public Health Okazaki, Kazuichi; Kansai Medical University Hirakata Hospital, Third Department of Internal Medicine, Division of Gastroenterology and Hepatology
Key Words:	Endoscopy: pancreato-biliary [ERCP] < Gastroenterology, double balloon endoscope, complications, adverse events, Roux-en-Y reconstruction, Billroth-II gastrectomy

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7 **Evaluation of complications after ERCP using a short type double balloon**
8
9 **endoscope in patients with altered gastrointestinal anatomy: a single-center**
10
11 **retrospective study of 1,576 procedures**
12
13
14
15
16
17

18 Running title: Complications after short type double-balloon endoscopic ERCP
19
20
21
22
23

24 Mitsuo Tokuhara MD¹, Masaaki Shimatani, MD, PhD¹, Toshiyuki Mitsuyama, MD, PhD¹,
25
26 Masataka Masuda, MD¹, Takashi Ito, MD¹, Sachi Miyamoto MD¹, Norimasa Fukata, MD,
27
28 PhD¹, Hideaki Miyoshi, MD, PhD¹, Tsukasa Ikeura, MD, PhD¹, Makoto Takaoka, MD,
29
30 PhD¹, Katsuyasu Kouda, MD, PhD², Kazuichi Okazaki, MD, PhD¹
31
32
33
34
35
36
37
38
39

40 **Author affiliations**
41

42 1 Third Department of Internal Medicine, Division of Gastroenterology and Hepatology,
43
44 Kansai Medical University Hirakata Hospital, Osaka, Japan.
45
46

47
48 2 Department of Hygiene and Public Health, Kansai Medical University Hirakata
49
50 Hospital, Osaka, Japan.
51
52
53
54
55

56
57 Corresponding author: Masaaki Shimatani, M.D. PhD.
58
59
60

1
2
3
4
5
6 Third Department of Internal Medicine, Division of Gastroenterology and Hepatology,
7

8
9 Kansai Medical University Hirakata Hospital,
10

11
12 2-5-1 Shinmachi, Hirakata, Osaka 573-1010, Japan.
13

14
15 Tel : +81-72-804-0101
16

17
18 Fax : +81-72-804-2524
19

20
21 E-mail : tokuhama@hirakata.kmu.ac.jp
22

23
24 Declaration of conflict of interest: None.
25

26
27 **Key Words**
28

29
30 ERCP; double balloon endoscope; complications; adverse events; Roux-en-Y
31
32 reconstruction; Billroth-II gastrectomy
33
34
35
36
37
38
39

40 Authors' contributions:

41
42 Mitsuo Tokuhara MD: drafted conception and design; wrote the manuscript.
43

44
45 Masaaki Shimatani, MD, PhD: drafted conception and design; substantive revision of the
46
47 manuscript.
48
49

50
51 Toshiyuki Mitsuyama, MD, PhD: acquisition of data.
52

53
54 Masataka Masuda, MD: acquisition of data.
55

56
57 Takashi Ito MD: acquisition of data.
58
59
60

1
2
3
4
5
6 Sachi Miyamoto MD: acquisition of data.
7

8
9 Norimasa Fukata, MD, PhD: statistical analysis.
10

11
12 Hideaki Miyoshi, MD, PhD: acquisition of data.
13

14
15 Tsukasa Ikeura, MD, PhD: acquisition of data.
16

17
18 Makoto Takaoka, MD, PhD: substantive revision of the manuscript.
19

20
21 Katsuyasu Kouda, MD, PhD: statistical analysis, substantive revision of the manuscript.
22

23
24 Kazuichi Okazaki, MD, PhD: substantive revision of the manuscript.
25

26
27
28
29
30 The guarantor author of the manuscript: Masaaki Shimatani
31

32
33
34
35
36 Conflicts of interest: The authors disclose no conflicts.
37

38
39
40
41
42 The financial supported: None.
43

44
45
46
47
48 Potential competing interests: None
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Background and Aims : Endoscopic retrograde cholangiopancreatography (ERCP) using balloon assisted endoscope (BAE) such as double balloon endoscope (DBE) is even effective for patients with surgically altered anatomy. Yet comprehensive studies on complications of ERCP using BAE (BAE-ERCP) have not been made. We analyzed the characteristics and the causes of complications of ERCP using DBE (DB-ERCP) procedures and aimed to suggest effective managements.

Methods : 1,576 procedures of DB-ERCP in 716 patients with surgically altered gastrointestinal anatomy in our hospital were evaluated retrospectively using a statistic analysis.

Results : The overall complication occurrence rate was 5.8%. By type of complications are; perforation 3.2%, mucosal laceration 0.5%, hemorrhage 1.0%, pancreatitis: 0.6%, respiratory disorder 0.4%, and others 0.2%. By type of surgical reconstruction methods were ; Roux-en-Y (R-Y) reconstruction with choledocho-jejunal anastomosis (CJA) 4.2%, R-Y without CJA 6.7%, pancreaticoduodenectomy (PD) 4.5%, pylorus preserving pancreaticoduodenectomy (PpPD) 4.2%, Billroth-II gastrectomy (B-II) 11.6%, and other reconstruction method (others) 7.4%. The contributing factors calculated by a multivariate analysis were B-II (odds ratio [OR]: 1.864, 95% confidence

1
2
3
4
5
6 interval [CI]: 1.001-3.471, $p = 0.050$), and the presence of naïve papilla (OR: 3.268, 95%
7
8
9 CI: 1.426-7.490, $p = 0.005$).

10
11
12 **Conclusions :** DB-ERCP is a safe method with a total complication rate of 5.8% which
13
14
15 could be considered within an acceptable range. The most common complication was
16
17
18 the injury of the digestive tract such as perforation. Affecting risk factors for
19
20
21 complications were B-II, and the presence of naïve papilla. DB-ERCP procedures
22
23
24 should be performed carefully of these factors.
25
26
27
28
29

30 **Introduction**

31
32
33 Endoscopic retrograde cholangiopancreatography (ERCP) is widely applied as
34
35
36 an endoscopic diagnostic and therapeutic modality for pancreatobiliary disease^{1,2}. Many
37
38
39 papers have reported its efficacy for patients with normal anatomy^{3,4}. Though as to in
40
41
42 patients with surgically altered gastrointestinal anatomy, it has been considered
43
44
45 technically challenging to thoroughly complete the ERCP-related interventions for
46
47
48 pancreatobiliary diseases⁵⁻⁷. In 2001, the innovative double-balloon assisted endoscopy
49
50
51 (DBE) was introduced as a new technique to allow visualization and intervention in the
52
53
54 entire small intestine⁸. The concept of balloon assisted endoscope (BAE) such as single
55
56
57 balloon endoscopy (SBE) has become widespread^{9,10} allowing ERCP in postoperative
58
59
60

1
2
3
4
5
6 patients. Many studies report the efficacy of BAE-ERCP¹¹⁻²⁵ and the endoscopic
7
8
9 treatment has come to be established as a standard therapeutic procedure for
10
11
12 pancreatobiliary disease in postoperative patients. Also many studies on complications
13
14
15 and risk factors have been reported focusing on conventional ERCP²⁶⁻³⁵ in patients with
16
17
18 normal anatomy, while only a few comprehensive studies on complications of BAE-
19
20
21 ERCP in patients with surgically altered gastrointestinal anatomy are reported.
22

23
24 In this present study, our aim was to retrospectively evaluate the characteristics
25
26 of complications by type of reconstruction methods analyzing 1,576 procedures of DB-
27
28 ERCP performed in our hospital from February 2006 to December 2018, and also to
29
30 suggest effective methods of management.
31
32
33
34
35
36
37
38

39 **PATIENTS AND METHODS**

40 *Patients*

41
42
43 From February 2006 to December 2018, 1,576 DB-ERCP procedures were
44
45
46 performed for pancreatobiliary diseases in 716 patients with altered gastrointestinal
47
48 anatomy in our hospital. Patient's conditions were evaluated with American society of
49
50 anesthesiologists physical status (ASA-PS)³⁶. All the procedures performed during the
51
52
53
54
55
56
57 last 154 months were analyzed retrospectively in this study. The types of reconstruction
58
59
60

1
2
3
4
5
6 methods were; Roux-en-Y (R-Y) with choledocho-jejunal anastomosis (CJA) 429
7
8
9 procedures in 134 patients, R-Y without CJA 404 procedures in 276 patients,
10
11
12 pancreaticoduodenectomy (PD) 287 procedures in 103 patients, pylorus preserving
13
14 pancreaticoduodenectomy (PpPD) 216 procedures in 78 patients, Billroth-II gastrectomy
15
16 (B-II) 172 procedures in 103 patients, and other reconstruction method (others) 68
17
18
19 procedures in 38 patients.
20
21
22
23

24 ***Endoscopes and instruments***

25
26
27 The DBE system is characterized by two balloons. The first is attached to the
28
29 tip of the endoscope, and the second is attached to the tip of the overtube. The balloons
30
31 can be inflated or deflated with a specially designed air pump controller with one-touch
32
33 controls with concurrent monitoring of the air pressure. Both are used to hold the
34
35 intestinal tract and are manipulated simultaneously to advance the scope into deep regions
36
37 by shortening the intestinal tract⁸. The balloon at the tip of the endoscope was always
38
39 kept fixed to the scope with string so that the DBE can be pulled out through the overtube
40
41 with the balloon attached.
42
43
44
45
46
47
48
49

50
51 There are two types of short type DBEs. One is the conventional short type
52
53 DBE (C-short DBE) (EI-530 B; FUJIFILM Co, Tokyo, Japan) with a 1,520 mm working
54
55 length and a 2.8 mm working channel. The other is the N-short DBE (EI-580 BT;
56
57
58
59
60

1
2
3
4
5
6 FUJIFILM Co, Tokyo, Japan) with a 1,550 mm working length and a 3.2 mm working
7
8 channel. A soft transparent hood (DH-17EN; FUJIFILM, Tokyo, Japan) was used when
9
10 necessary. C-short DBE or N-short DBE was used for DB-ERCP in this study.
11
12
13
14

15 **Methods**

16
17
18 Patients were laid in the prone position and premedicated with midazolam (0.15–
19
20 0.3 mg/kg), pentazocine (15 mg), and scopolamine butylbromide (10-20mg) on an as-
21
22 needed basis. CO₂ insufflation was used in all procedures. PtcCO₂ was measured by
23
24 non-invasive sensor (KOHKEN, Tokyo, Japan) throughout DB-ERC. Patients were
25
26 simultaneously monitored for SpO₂ and pulse rate, as well as intermittent measurement
27
28 of blood pressure³⁷. DB-ERCP involved the following two major steps. The first step
29
30 was to insert an endoscope deeply to the blind end. The second step was to perform
31
32 ERCP-related interventions. Any adverse events that occurred during DB-ERCP or post
33
34 DB-ERCP procedures were recorded as complications.
35
36
37
38
39
40
41
42
43
44

45 DB-ERCP was performed by three endoscopists with more than 500 experiences
46
47 with conventional ERCP. One is an experienced endoscopist with more than 100 cases
48
49 of DB-ERCP, the other is with 50-99 cases of DB-ERCP, and the other is with less than
50
51 49 cases of DB-ERCP. Neither the effects of different level of experience of those
52
53 endoscopists on the complication nor the effects of different skills of the endoscopic
54
55
56
57
58
59
60

1
2
3
4
5
6 technicians on the complication was recognized.
7
8

9
10 ***Definitions and outcome measurement***
11

12 The primary outcome was the complication occurrence rate. The secondary
13
14
15 outcome was the contributing factors for complication, and its control after occurrence.
16
17

18 Procedure time was defined as from DBE insertion to withdrawal.
19
20 Management time against complication was not included in the procedure time.
21
22 Perforations were defined by the presence of gas or luminal contents outside the
23
24 gastrointestinal tract by any radiographic technique. Basically, the presence of free air
25
26 was checked by the X-ray during the procedure (especially the free air around the kidney
27
28 and iliopsoas). As free air caused by microperforation is difficult to be detected,
29
30 abdominal computed tomography (CT) scan was applied in all cases where lacerations
31
32 were visually found by endoscopy or patients had symptoms such as abdominal pain after
33
34 procedures. Perforations were defined according to the classification by Stapfer et al.:
35
36 type I, perforations of the lateral or medial wall of the intestine; type II, perforations with
37
38 perivaterian injuries; type III, perforations with distal bile duct injuries related to
39
40 guidewire-basket instrumentation; type IV, retroperitoneal air alone³⁴. Intestinal
41
42 lacerations without the presence of gas or luminal contents outside the gastrointestinal
43
44 tract were defined as mucosal laceration. Post DB-ERCP pancreatitis (PEP) was
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 defined by new or worsened abdominal pain requiring prolonged admission with
7
8
9 increased serum levels of pancreatic enzymes (amylase or lipase) higher than twice of the
10
11
12 normal upper limit after procedure³⁸. Bleeding that required endoscopic hemostasis
13
14
15 during procedures or presences of clinical evidence of bleeding such as melena or
16
17
18 hematemesis, with an associated decrease of at least 2 g per deciliter in the hemoglobin
19
20
21 concentration, or the need for a blood transfusion were defined as hemorrhage³⁸. The
22
23
24 condition of hypoxemia, hypercapnia, and respiratory arrest need for emergence from
25
26
27 deep sedation or tracheal intubation was defined as respiratory disorder. Other
28
29
30 complications were defined as others.

31
32
33 ***Management of type II, III, and IV perforations and mucosal lacerations (Endoscopic***
34
35
36 ***treatments)***

37
38
39 If the mucosal injury site is visible, clipping disclosure was performed. In
40
41
42 addition, endoscopic nasal biliary drainage tube (ENBD) was inserted into the bile duct
43
44
45 and the guide wire (GW) was placed at the blind end (Figure 1A). Then, with the
46
47
48 overtube remaining near the blind end, the scope was withdrawn while ENBD and GW
49
50
51 were placed (Figure 1B). Finally, a nasal intestinal drainage tube was placed near the
52
53
54 blind end under GW guidance through the remaining overtube (Figure 1C).

55
56
57 This study was conducted accordingly to the Declaration of Helsinki, approved
58
59
60

1
2
3
4
5
6 by Institutional Review Board (IRB). The method, its effectiveness, and the possibility
7
8
9 of complications were explained to the patients and the written informed consent was
10
11
12 obtained before the procedure.
13
14
15
16
17

18 **Statistical analysis**

19
20
21 In order to make comparison in proportion between patients with each surgical
22
23 gastrointestinal reconstruction and patients without each surgical gastrointestinal
24
25 reconstruction, the chi-square test was used. For assessment of difference in mean
26
27 values between patients with complication and those without complication, the unpaired
28
29 t-test was used. For comparison in proportion of complications in patients with potential
30
31 confounding factors and without those factors, the chi-square test was used. Variables
32
33 with p values of <0.1 in these analyses were considered as confounding factors between
34
35 a predictor and an outcome. Multivariate analysis was performed using logistic
36
37 regression analysis after adjusting those confounding factors. P-values of <0.05 were
38
39 considered to indicate statistical significance. For comparison in proportion of
40
41 complications between the initial procedure and recurrent procedures, the chi-square test
42
43 was used. All analyses were performed using SPSS Statistics Desktop for Japan,
44
45
46
47
48
49
50
51
52
53
54
55
56
57 Version 22 (IBM Japan, Ltd., Tokyo, Japan).
58
59
60

Result

Table 1 shows the patients' medical background. As the reason for reconstructive surgery, gastroduodenal disease (malignant) was the most common. By type of surgical reconstruction method, R-Y with CJA 429 procedures was the most common closely followed by R-Y without CJA 404 procedures, and others 68 procedures included double tract 19 procedures, gastrojejunal bypass 17 procedures, Imanaga method 13 procedure, choledoco-duodenostomy 17 procedures, B-II gastrectomy with R-Y reconstruction 1 procedure and double R-Y 1 procedure. Regarding indications for DB-ERCP, CJA stenosis with stones was the most common followed by common bile duct stones.

Complication occurrence rate

Table 2 shows the characteristics of complications. The overall complication occurrence rate was 5.8%. By type of reconstruction method, R-Y with CJA 4.2%, R-Y without CJA 6.7%, PD 4.5%, PpPD 4.2%, B-II 11.6% and others 7.4%. In B-II cases, the occurrence rate was significantly higher than those in others ($P < 0.001$). By characteristics of complications, perforation was the highest at 3.2%, and all other complications were less than 1%. About half the complications were perforation, most of which were type II, III, and IV perforation (48.9%) (Figure 2).

Contributing factors of complication occurrence

Table 3 shows the contributing factors of complications. The age, sex, procedure time, poor patient's status (ASA-PS ≥ 3), using old type endoscope (EI-530B), type of reconstruction method, state of papilla Vater, and indication for DB-ERCP were analyzed. By the multivariate analysis performed by adjusting the confounding factors, B-II (odds ratio [OR]: 1.864, 95% confidence interval [CI]: 1.001-3.471, $p = 0.050$), and the presence of naïve papilla (OR: 3.268, 95% CI: 1.426-7.490, $p = 0.005$) were proved to be statistically significant risk factors. The complication occurrence rate in the initial procedural cases was 9.2% (66/716 procedures), while in the recurrent procedural cases was 3.0% (26/860 procedures), suggesting the former was significantly higher ($p < 0.001$).

Management and prognosis of complications

Table 4 shows the management and prognosis of complications. As the management of complications, endoscopic treatment was the most common at 56.5%. Emergency surgery was necessary in 5.4%. As management for perforation cases in our hospital, surgery was basically selected for type I perforation, and endoscopic treatment was basically selected for type II, III, and IV perforation. Hemorrhages occurred in total of 15 cases, hemorrhage of papilla Vater portion due to endoscopic sphincterotomy (EST) 10 cases, hemorrhage of choledocho-jejunal anastomosis portion due to balloon dilatation

1
2
3
4
5
6 of choledocho-jejunal anastomosis 4 cases, intestinal mucosal hemorrhage due to
7
8
9 mucosal suction during scope insertion 1 case. For hemorrhages, either endoscopic
10
11
12 hemostasis or conservative treatment was principally selected as follows; clipping 1 case,
13
14
15 hypertonic saline-epinephrine (HSE) injection 7 cases, balloon oppression 3 cases.
16
17
18 Only in 1 case where endoscopic hemostasis was not possible, transcatheter arterial
19
20
21 embolization (TAE) was applied. Regarding the PEP, most cases were mild and severe
22
23
24 pancreatitis occurred only in 1 case where intensive care was required. Respiratory
25
26
27 disorder occurred as follows; CO₂ narcosis in 4 cases, requiring endotracheal intubation
28
29
30 in 3 cases. Others were caused by deep sedation. In 2 cases, CO₂ supply was changed
31
32
33 to room air supply, and the other 2 cases were awoken from deep sedation. As other
34
35
36 minor complications, drainage of the thoracic cavity was required in a case of
37
38
39 subcutaneous emphysema and right pneumothorax, and for the iatrogenic choledocho-
40
41
42 duodenal fistula generated during endoscopic papillary large balloon dilation (EPLBD),
43
44
45 plastic stent placement was performed. Among all the complications cases, 7 patients
46
47
48 (7.6%) died, the overall mortality rate was 1.0% (7 of 716 patients). However, the major
49
50
51 cause of death was due to exacerbation of primary disease or aspiration pneumonia after
52
53
54 the treatment for complications. DB-ERCP was regarded as directly related to the cause
55
56
57 of death in 2 patients (0.3%; 2 of 716 patients).
58
59
60

1
2
3
4
5
6
7 The mean period of extended hospitalization of complications cases was $12.9 \pm$
8
9 15.0 days. PEP cases resulted in the longest (27.6 ± 28.9 days), followed by type II, III,
10
11 and IV perforation cases (15.4 ± 12.3 days).
12
13
14
15
16
17

18 **Discussion**

19
20
21 ERCP in patients with surgically altered anatomy is considered technically more
22
23 challenging than in patients with normal anatomy posing a higher risk of complications.
24
25 Complications of ERCP-related interventions for normal anatomy (conventional ERCP;
26
27 C-ERCP) have been reported in many studies^{26-35,38}, although, there have been few
28
29 systematic reports for surgically altered anatomy^{6,18,21,39-44}.
30
31
32
33
34
35
36 Furthermore the complication rates of BAE-ERCP reported from existing studies ranged
37
38 widely between (4.8-12.4%)^{6,12,18,21,39-44}. All have been reported in a small or medium
39
40 case series.
41
42
43
44

45 The first multicenter prospective study for 311 procedures from Japan reported⁴⁵
46
47 the complication rate was 10.6%, including injury of digestive tract 3.9% (perforation
48
49 2.3% inclusive) as most common complication. The complication rate was 5.8% in our
50
51 study, showing a lower rate compared to that in the existing studies.
52
53
54
55

56
57 According to the latest retrospective cohort study from 2014 using a large data
58
59
60

1
2
3
4
5
6 base of 2,715 patients who underwent C-ERCP²⁹, the complication rate was 12 %
7
8
9 suggesting that DB-ERCP should not bring about any higher when compared with C-
10
11
12 ERCP. However, since more of recurrent procedural cases were performed with DB-
13
14
15 ERCP, in comparison of the complication rates limited to the DB-ERCP initial cases and
16
17
18 C-ERCP initial cases in order to eliminate the possible biases, the former was 9.2%
19
20
21 (66/716 procedures), which was almost equivalent to that of C-ERCP. Therefore DB-
22
23
24 ERCP was no more complication-risk-posing than C-ERCP, suggesting it is a safe
25
26
27 therapeutic modality (Table 3).
28
29

30 In addition, by characteristic of complications of C-ERCP were; pancreatitis
31
32
33 4.9%, bleeding 4.5%, and perforation 0.11%, showing their most common complication
34
35
36 was pancreatitis, while in our study was perforation, which clearly showed the difference
37
38
39 in characteristic of complications. The presence of postoperative adhesion is reported
40
41
42 to increase the risk of perforation significantly⁴⁶, and the risk of perforation in DB-ERCP
43
44
45 is higher than that in C-ERCP. Thus, it was suggested DB-ERCP should be performed
46
47
48 carefully for the risk of perforation.
49
50

51 As the reference of management to control perforation, European Society of
52
53
54 Gastrointestinal Endoscopy (ESGE) Position Statement is applied in our hospital³³.
55
56
57 For type I perforation, endoscopic closure is recommended when the lesion of perforation
58
59
60

1
2
3
4
5
6
7 can be identified immediately, endoscopic closure is recommended, however, should an
8
9 endoscopic closure fail, surgery must be immediately applied. There is a report
10
11 suggesting that endoscopic closure for obvious perforation should be considered carefully
12
13 because the laceration needs to be closed tightly including the submucosa³¹, therefore, in
14
15 our hospital, surgical treatment is basically selected. For type II, III, and IV perforation,
16
17 it is recommended to place an intestinal drainage tube and bile duct drainage tube to
18
19 reduce the leak of intestinal fluid and bile juice into the abdominal cavity and
20
21 retroperitoneal space, and to administer antibiotics^{33,34}. In this study, endoscopic
22
23 intestinal and biliary drainage and antibiotics were applied for type II, III, and IV
24
25 perforation as described above.
26
27
28
29
30
31
32
33
34
35

36 Regarding the respiratory disorder was observed in 7 cases (0.4%), including
37
38 CO₂ narcosis in 4 cases. There is a study reporting appropriate monitoring and
39
40 management of hemodynamics by capnography monitor and non-invasive continuous
41
42 transcutaneous carbon dioxide monitor (PtcCO₂ measurement) are necessary for early
43
44 detection of respiratory disorders including CO₂ narcosis³⁷, and monitoring with the
45
46 PtcCO₂ monitor as well as a pulse oximeter should be necessary during DB-ERCP
47
48
49
50
51
52
53
54
55 procedure.

56
57 In this study, B-II and the presence of naïve papilla were the factors affecting
58
59
60

1
2
3
4
5
6 complications in DB-ERCP. Itoi et al⁴⁷. also reported that naïve papilla cases were
7
8
9 difficult to accomplish the procedure from bile duct cannulation to ERCP-related
10
11
12 interventions. Thus, DB-ERCP for naïve papilla cases is technically challenging and
13
14
15 must be performed carefully for possible occurrence of the complication.
16
17

18
19 In B-II cases, the complication occurrence rate and the perforation rate were
20
21 significantly the highest among all reconstruction methods. There are short afferent
22
23 loop (SAL) type and long afferent loop (LAL) type for B-II. The distance from the
24
25 gastro-jejunal anastomosis to the Treitz ligament in the afferent loop and the strength of
26
27 the fixation point of the anastomosis are different. The distance between the gastro-
28
29 jejunal anastomosis and Treitz ligament in SAL type is extremely short because the
30
31 afferent loop is lifted and sutured above the superior margin of the resected stomach to
32
33 prevent reflux of meal content into the afferent loop. Therefore, it is suggested that the
34
35 perforation risk is increased by a strong pushing force when inserting a scope into the
36
37 afferent loop (Figure 3A). On the other hand, LAL type has a Braun anastomosis that
38
39 expands like a hole near the pelvic cavity, and the distance between the gastro-jejunal
40
41 anastomosis and the Treitz ligament is long, which allow the afferent loop to be not much
42
43 tensioned by pushing force to advance scope (Figure 3B). In our study, all the
44
45 perforation cases in B-II were SAL type.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 In addition, the afferent loop is rarely over-tensioned by a pushing force in R-Y
8
9 reconstruction cases when the scope is inserted. The distance between the Y-
10
11 anastomosis fixed loosely in the abdominal cavity and Treitz ligament is basically long
12
13 (Figure 3C). Therefore, it is considered that the risk of perforation caused by scope
14
15 advancement is low.
16
17
18
19

20
21 Regarding 2 cases of complications directly related death, in one case,
22
23 perforation could not be detected during the procedure and no intestinal or bile duct
24
25 drainage tube was placed. On the next day, a perforation was found and the patient died
26
27 of peritonitis. This case suggested that placing at least intestinal and bile duct drainage
28
29 tubes could be useful for possible perforation cases. In the other case, the patient had
30
31 poor cardiac function and had undergone antithrombotic therapy. Hemorrhagic shock
32
33 suddenly occurred at night, and the patient was transferred to our hospital for endoscopic
34
35 treatment, but died because hemostasis was too late. This suggested that it was
36
37 necessary to pay attention especially to patients on antithrombotic therapy and in cases
38
39 after performing EST during DB-ERCP, patients should be hospitalized in a facility
40
41 where BAE can be used and the endoscopic hemostasis is possible.
42
43
44
45
46
47
48
49
50
51
52

53
54 The limitation of this study is being a retrospective single center study, however,
55
56 the study evaluating 1,500 procedures is the first large case report up to date. Yet,
57
58
59
60

1
2
3
4
5
6 further studies of a larger-scale prospective multiple center are necessary.
7
8
9

10 11 12 **Conclusion** 13

14
15 In this study, complications of DB-ERCP in large cases exceeding 1,500
16 procedures were evaluated. The overall complication occurrence rate was 5.8%, which
17
18 was no significant different compared to the frequency of complications in C-ERCP in
19 patients with normal anatomy. The most common complication was gastrointestinal
20 damages such as perforation, however even if complications occurred, most cases could
21 be recovered if appropriately handled. The affecting factors for complications were B-
22 II, and the presence of naïve papilla. Thus, complication of DB-ERCP was within an
23 acceptable range and the procedures should be performed carefully of risk-posing factors.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Cotton PB, Blumgart LH, Davies GT, et al. Cannulation of papilla of vater via fiber-
duodenoscope. Assessment of retrograde cholangiopancreatography in 60 patients.
Lancet. 1972;1(7741):53-58.
2. Takagi K, Ikeda S, Nakagawa Y, Sakaguchi N, Takahashi T. Retrograde
pancreatography and cholangiography by fiber duodenoscope. *Gastroenterology*.
1970;59(3):445-452.
3. Freeman ML, Guda NM. ERCP cannulation: a review of reported techniques.
Gastrointest Endosc. 2005;61(1):112-125.
4. Suissa A, Yassin K, Lavy A, et al. Outcome and early complications of ERCP: a
prospective single center study. *Hepatogastroenterology*. 2005;52(62):352-355.
5. Forbes A, Cotton PB. ERCP and sphincterotomy after Billroth II gastrectomy. *Gut*.
1984;25(9):971-974.
6. Shimatani M, Matsushita M, Takaoka M, et al. Effective "short" double-balloon
enteroscope for diagnostic and therapeutic ERCP in patients with altered
gastrointestinal anatomy: a large case series. *Endoscopy*. 2009;41(10):849-854.
7. Shimatani M, Takaoka M, Ikeura T, Mitsuyama T, Okazaki K. Evaluation of
endoscopic retrograde cholangiopancreatography using a newly developed short-type
single-balloon endoscope in patients with altered gastrointestinal anatomy. *Dig
Endosc*. 2014;26 Suppl 2:147-155.
8. Yamamoto H, Sekine Y, Sato Y, et al. Total enteroscopy with a nonsurgical steerable
double-balloon method. *Gastrointestinal Endoscopy*. 2001;53(2):216-220.
9. Kobayashi K, Haruki S, Sada M, Katsumata T, Saigenji K. [Single-balloon
enteroscopy]. *Nihon Rinsho*. 2008;66(7):1371-1378.
10. Upchurch BR, Vargo JJ. Single-balloon enteroscopy. *Gastrointest Endosc Clin N Am*.
2009;19(3):335-347.
11. Cho S, Kamalporn P, Kandel G, Kortan P, Marcon N, May G. 'Short' double-balloon
enteroscope endoscopic retrograde cholangiopancreatography in patients with a
surgically altered upper gastrointestinal tract. *Can J Gastroenterol*. 2011;25(11):615-
619.
12. De Koning M, Moreels TG. Comparison of double-balloon and single-balloon
enteroscope for therapeutic endoscopic retrograde cholangiography after Roux-en-Y
small bowel surgery. *BMC Gastroenterol*. 2016;16(1):98.
13. Itoi T, Ishii K, Sofuni A, et al. Long- and short-type double-balloon enteroscopy-
assisted therapeutic ERCP for intact papilla in patients with a Roux-en-Y

- 1
2
3
4
5
6 anastomosis. *Surg Endosc.* 2011;25(3):713-721.
- 7 14. Katanuma A, Isayama H. Current status of endoscopic retrograde
8 cholangiopancreatography in patients with surgically altered anatomy in Japan:
9 questionnaire survey and important discussion points at Endoscopic Forum Japan
10 2013. *Dig Endosc.* 2014;26 Suppl 2:109-115.
- 11 15. Kato H, Tsutsumi K, Harada R, Okada H, Yamamoto K. Short double-balloon
12 enteroscopy is feasible and effective for endoscopic retrograde
13 cholangiopancreatography in patients with surgically altered gastrointestinal
14 anatomy. *Dig Endosc.* 2014;26 Suppl 2:130-135.
- 15 16. Koshitani T, Matsuda S, Takai K, et al. Direct cholangioscopy combined with double-
16 balloon enteroscope-assisted endoscopic retrograde cholangiopancreatography.
17 *World J Gastroenterol.* 2012;18(28):3765-3769.
- 18 17. Monkemuller K, Bellutti M, Neumann H, Malfertheiner P. Therapeutic ERCP with
19 the double-balloon enteroscope in patients with Roux-en-Y anastomosis. *Gastrointest*
20 *Endosc.* 2008;67(6):992-996.
- 21 18. Monkemuller K, Fry LC, Bellutti M, Neumann H, Malfertheiner P. ERCP with the
22 double balloon enteroscope in patients with Roux-en-Y anastomosis. *Surg Endosc.*
23 2009;23(9):1961-1967.
- 24 19. Moreels TG, Pelckmans PA. Comparison between double-balloon and single-balloon
25 enteroscopy in therapeutic ERC after Roux-en-Y entero-enteric anastomosis. *World*
26 *J Gastrointest Endosc.* 2010;2(9):314-317.
- 27 20. Osoegawa T, Motomura Y, Akahoshi K, et al. Improved techniques for double-
28 balloon-enteroscopy-assisted endoscopic retrograde cholangiopancreatography.
29 *World J Gastroenterol.* 2012;18(46):6843-6849.
- 30 21. Parlak E, Cicek B, Disibeyaz S, et al. Endoscopic retrograde cholangiography by
31 double balloon enteroscopy in patients with Roux-en-Y hepaticojejunostomy. *Surg*
32 *Endosc.* 2010;24(2):466-470.
- 33 22. Shimatani M, Takaoka M, Matsushita M, Okazaki K. Endoscopic approaches for
34 pancreatobiliary diseases in patients with altered gastrointestinal anatomy. *Dig*
35 *Endosc.* 2014;26 Suppl 1:70-78.
- 36 23. Shimatani M, Takaoka M, Okazaki K. Tips for double balloon enteroscopy in patients
37 with Roux-en-Y reconstruction and modified child surgery. *J Hepatobiliary Pancreat*
38 *Sci.* 2014;21(4):E22-28.
- 39 24. Shimatani M, Takaoka M, Tokuhara M, Miyoshi H, Ikeura T, Okazaki K. Review of
40 diagnostic and therapeutic endoscopic retrograde cholangiopancreatography using
41 several endoscopic methods in patients with surgically altered gastrointestinal
42 anatomy. *Surg Endosc.* 2011;25(3):713-721.
- 43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 anatomy. *World J Gastrointest Endosc.* 2015;7(6):617-627.
- 7 25. Shimatani M, Tokuhara M, Kato K, et al. Utility of newly developed short-type
8 double-balloon endoscopy for endoscopic retrograde cholangiography in postoperative
9 patients. *J Gastroenterol Hepatol.* 2017;32(7):1348-1354.
- 10 26. Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis:
11 A prospective, multicenter study. *Gastrointestinal Endoscopy.* 2001;54(4):425-434.
- 12 27. Freeman ML, Nelson DB, Sherman S, et al. Same-day discharge after endoscopic
13 biliary sphincterotomy: observations from a prospective multicenter complication
14 study. *Gastrointestinal Endoscopy.* 1999;49(5):580-586.
- 15 28. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary
16 sphincterotomy. *N Engl J Med.* 1996;335(13):909-918.
- 17 29. Katsinelos P, Lazaraki G, Chatzimavroudis G, et al. Risk factors for therapeutic
18 ERCP-related complications: an analysis of 2,715 cases performed by a single
19 endoscopist. *Ann Gastroenterol.* 2014;27(1):65-72.
- 20 30. Lee MH, Tsou YK, Lin CH, et al. Predictors of re-bleeding after endoscopic
21 hemostasis for delayed post-endoscopic sphincterotomy bleeding. *World J*
22 *Gastroenterol.* 2016;22(11):3196-3201.
- 23 31. Morgan KA, Fontenot BB, Ruddy JM, Mickey S, Adams DB. Endoscopic retrograde
24 cholangiopancreatography gut perforations: when to wait! When to operate! *Am Surg.*
25 2009;75(6):477-483; discussion 483-474.
- 26 32. Park SM. Recent Advanced Endoscopic Management of Endoscopic Retrograde
27 Cholangiopancreatography Related Duodenal Perforations. *Clin Endosc.*
28 2016;49(4):376-382.
- 29 33. Paspatis GA, Dumonceau JM, Barthet M, et al. Diagnosis and management of
30 iatrogenic endoscopic perforations: European Society of Gastrointestinal Endoscopy
31 (ESGE) Position Statement. *Endoscopy.* 2014;46(8):693-711.
- 32 34. Stapfer M, Selby RR, Stain SC, et al. Management of duodenal perforation after
33 endoscopic retrograde cholangiopancreatography and sphincterotomy. *Ann Surg.*
34 2000;232(2):191-198.
- 35 35. Vezakis A, Fragulidis G, Polydorou A. Endoscopic retrograde
36 cholangiopancreatography-related perforations: Diagnosis and management. *World*
37 *J Gastrointest Endosc.* 2015;7(14):1135-1141.
- 38 36. Mayhew D, Mendonca V, Murthy BVS. A review of ASA physical status - historical
39 perspectives and modern developments. *Anaesthesia.* 2019;74(3):373-379.
- 40 37. Miyoshi H, Shimatani M, Kato K, et al. Transcutaneous monitoring of partial
41 pressure of carbon dioxide during endoscopic retrograde cholangiopancreatography
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 using a double-balloon endoscope with carbon dioxide insufflation under conscious
7 sedation. *Dig Endosc.* 2014;26(3):436-441.
- 8
9 38. Cotton PB, Eisen GM, Aabakken L, et al. A lexicon for endoscopic adverse events:
10 report of an ASGE workshop. *Gastrointest Endosc.* 2010;71(3):446-454.
- 11
12 39. Chua TJ, Kaffes AJ. Balloon-assisted enteroscopy in patients with surgically altered
13 anatomy: a liver transplant center experience (with video). *Gastrointest Endosc.*
14 2012;76(4):887-891.
- 15
16 40. Moreels TG, Hubens GJ, Ysebaert DK, Op de Beeck B, Pelckmans PA. Diagnostic
17 and therapeutic double-balloon enteroscopy after small bowel Roux-en-Y
18 reconstructive surgery. *Digestion.* 2009;80(3):141-147.
- 19
20 41. Raithel M, Dormann H, Naegel A, et al. Double-balloon-enteroscopy-based endoscopic
21 retrograde cholangiopancreatography in post-surgical patients. *World J*
22 *Gastroenterol.* 2011;17(18):2302-2314.
- 23
24 42. Shah RJ, Smolkin M, Yen R, et al. A multicenter, U.S. experience of single-balloon,
25 double-balloon, and rotational overtube-assisted enteroscopy ERCP in patients with
26 surgically altered pancreaticobiliary anatomy (with video). *Gastrointest Endosc.*
27 2013;77(4):593-600.
- 28
29 43. Siddiqui AA, Chaaya A, Shelton C, et al. Utility of the short double-balloon
30 enteroscope to perform pancreaticobiliary interventions in patients with surgically
31 altered anatomy in a US multicenter study. *Dig Dis Sci.* 2013;58(3):858-864.
- 32
33 44. Wang AY, Sauer BG, Behm BW, et al. Single-balloon enteroscopy effectively enables
34 diagnostic and therapeutic retrograde cholangiography in patients with surgically
35 altered anatomy. *Gastrointest Endosc.* 2010;71(3):641-649.
- 36
37 45. Shimatani M, Hatanaka H, Kogure H, et al. Diagnostic and Therapeutic Endoscopic
38 Retrograde Cholangiography Using a Short-Type Double-Balloon Endoscope in
39 Patients With Altered Gastrointestinal Anatomy: A Multicenter Prospective Study
40 in Japan. *Am J Gastroenterol.* 2016;111(12):1750-1758.
- 41
42 46. Patel MK, Horsley-Silva JL, Gomez V, Stauffer JA, Stark ME, Lukens FJ. Double
43 balloon enteroscopy procedure in patients with surgically altered bowel anatomy:
44 analysis of a large prospectively collected database. *J Laparoendosc Adv Surg Tech*
45 *A.* 2013;23(5):409-413.
- 46
47 47. Itoi T, Ishii K, Sofuni A, et al. Single-balloon enteroscopy-assisted ERCP in patients
48 with Billroth II gastrectomy or Roux-en-Y anastomosis (with video). *Am J*
49 *Gastroenterol.* 2010;105(1):93-99.
- 50
51
52
53
54
55
56
57
58
59
60

Figure legends

Figure 1: Management of type II, III, and IV perforations and mucosal lacerations
(Endoscopic treatments)

A; Nasal biliary drainage tube (ENBD) was inserted into the bile duct and the guide wire (GW) was placed at the blind end.

B; ENBD and GW were placed with the overtube remaining near the blind end.

C; Nasal intestinal drainage tube was placed near the blind end under GW guidance through the remaining overtube.

Figure 2: Complication occurrence by characteristics

Figure 3: Scheme of Billroth II gastrectomy and Roux-en-Y reconstruction

○; Firm fixed point (Gastro-jejunal anastomosis, Lifting of the afferent loop, and Treitz ligament).

□; Loose fixed point (Braun anastomosis, Y-anastomosis).

→; Direction of the scope.

A; Scheme of short afferent loop (SAL) type Billroth II gastrectomy

1
2
3
4
5
6 The distance between the gastro-jejunal anastomosis and Treitz ligament in B-II SAL
7
8
9 type is extremely short and tight.
10

11
12 B; Scheme of long afferent loop (LAL) type Billroth II gastrectomy
13

14
15 The distance between the gastro-jejunal anastomosis and the Treitz ligament in B-II LAL
16
17
18 type is long and loose.
19

20
21 C; Scheme of Roux-en-Y reconstruction
22

23
24 The distance between the gastro-jejunal anastomosis and the Treitz ligament in Roux-en-
25
26
27 Y reconstruction is long and loose.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60






Figure 1: Management of type II, III, and IV perforations and mucosal lacerations (Endoscopic treatments) A; Nasal biliary drainage tube (ENBD) was inserted into the bile duct and the guide wire (GW) was placed at the blind end.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




B; ENBD and GW were placed with the overtube remaining near the blind end.



C; Nasal intestinal drainage tube was placed near the blind end under GW guidance through the remaining overtube.




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41



Treitz ligament



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

1
2 **Table 1** Patients' medical background

	R-Y with CJA	R-Y without CJA	PD	PpPD	B-II	others	Total
	n=429	n=404	n = 287	n = 216	n = 172	n = 68	n = 1576
5 Sex, male, n (%)	200 (46.6)	345 (85.4)	203 (70.7)	123 (56.9)	146 (84.9)	36 (52.9)	1053 (66.8)
6 Age, mean ± SD, years	57.3 ± 16.7	73.1 ± 9.2	70.3 ± 9.5	66.9 ± 13.1	74.2 ± 9.1	60.7 ± 20.3	67.0 ± 14.4
7 Reason for surgical gastrointestinal reconstruction							
8 Gastric cancer	19	388	1	2	49	31	490
9 Congenital biliary dilatation	171	1	0	0	0	1	173
10 Intraductal papillary mucinous neoplasm	8	0	79	75	0	0	162
11 Bile duct cancer	83	2	19	44	1	5	154
12 Pancreatic cancer	5	1	90	51	0	5	152
13 Gastro-duodenal ulcer	2	5	2	0	120	5	134
14 Trauma and injury due to surgical operation	57	1	3	8	2	0	71
15 Papilla of Vater cancer	0	0	35	14	0	0	49
16 Pancreaticobiliary maljunction	39	0	0	0	0	3	42
17 Duodenal cancer	0	1	28	7	0	1	37
18 Pancreatic benign tumor	0	0	10	4	0	12	26
19 Common bile duct stones	23	2	0	0	0	0	25
20 Chronic pancreatitis	0	0	11	0	0	0	11
21 Neuroendocrine tumor	0	0	4	5	0	0	9
22 Hepatic stones	8	0	0	0	0	0	8
23 Metastatic liver tumor	6	0	0	0	0	0	6
24 Insulinoma	0	0	0	5	0	0	5
25 Gastrointestinal stromal tumor	0	0	4	0	0	0	4
26 Hepatic blastoma	0	0	0	0	0	4	4
27 Liver transplantation	2	0	0	0	0	0	2
28 Mirizzi syndrome	2	0	0	0	0	0	2
29 Others	4	3	1	1	0	1	10
30 Indication for DB-ERCP							
31 CJA stenosis with stones	226	1	105	83	1	5	421
32 Common bile duct stones	0	251	0	0	118	16	385
33 CJA stenosis without stones	136	3	101	92	6	4	342
34 Malignant biliary stricture	24	112	18	10	28	18	210
35 Pancreatic disease	0	5	31	15	3	14	68
36 Others	43	32	32	16	16	11	150

39 DB-ERCP, double balloon assisted endoscopic retrograde cholangiopancreatography; R-Y, Roux-en-Y reconstruction; CJA, choledocho-jejunal anastomosis;

40 PD, pancreaticoduodenectomy; PpPD, pylorus preserving pancreaticoduodenectomy, B-II; Billroth-II gastrectomy.

41

42

43

44

45

46

Table 2 Characteristics of complications

	R-Y with CJA, n=429	R-Y without CJA, n=404	PD, n=287	PpPD, n=216	B-II, n=172	others, n=68
Complication, n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Perforation, 50 (3.2)	11 (2.6)	16 (4.0)	3 (1.0)	6 (2.8)	13 (7.6)	1 (1.5)
Type I, 5 (0.3)	0 (0)	2 (0.5)	0 (0)	1 (0.5)	2 (1.2)	0 (0)
Type II, III and IV, 45 (2.9)	11 (2.6)	14 (3.5)	3 (1.0)	5 (2.3)	11 (6.4)	1 (1.5)
Mucosal laceration, 8 (0.5)	2 (0.5)	0 (0)	5 (1.7)	0 (0)	1 (0.6)	0 (0)
Hemorrhage, 15 (1.0)	2 (0.5)	6 (1.5)	1 (0.3)	2 (0.9)	2 (1.2)	2 (2.9)
Pancreatitis, 9 (0.6)	1 (0.2)	4 (1.0)	1 (0.3)	0 (0)	3 (1.7)	0 (0)
Respiratory disorder, 7 (0.4)	0 (0)	1 (0.2)	3 (1.0)	1 (0.5)	0 (0)	2 (2.9)
Others, 3 (0.2)	2 (0.5)	0 (0)	0 (0)	0 (0)	1 (0.6)	0 (0)
Total, 92 (5.8)	18 (4.2)	27 (6.7)	13 (4.5)	9 (4.2)	20 (11.6)	5 (7.4)
	P^a = 0.089	P^a = 0.401	P^a = 0.296	P^a = 0.26	P^a < 0.001	P^a = 0.586

Type I, Stapfer's classification type I (perforations of the lateral or medial wall of the intestine); type II, Stapfer's classification type II (perforations with perivaterian injuries); type III, Stapfer's classification type III (perforations with distal bile duct injuries related to guidewire-basket instrumentation); type IV, Stapfer's classification type IV (retroperitoneal air alone).

^aTo compare proportion between patients with each surgical gastrointestinal reconstruction and patients without each surgical gastrointestinal reconstruction, the chi-square test was used.

Table 3 Contributing factors of complications

	Clinical success - rate, n (%)	Non complication	Complication	Complication - rate	Univariate analysis	Multivariate analysis	Odds ratio
	Total; 1502 (95.3)	n = 1484	n = 92	5.8%	p-value	p-value	(95% CI)
Age, mean ± SD, years	—	66.8 ± 14.5	70.6 ± 13.7	—	0.015 ^a	0.169 ^c	
Sex, male, n=1053	1004 (95.3)	988	65	6.2%	0.421 ^b		
Procedure time (excluded treatment time for complication)	—	75.8 ± 49.6	86.1 ± 51.2	—	0.054 ^a	0.118 ^c	
Poor patient's status (ASA-PS ≥3), n = 240	218 (90.8)	225	15	6.3%	0.767 ^b		
Using old type endoscope (EI-530B) , n = 966	916 (94.8)	900	66	6.8%	0.034 ^b	0.144 ^c	
Reconstruction method							
<i>R-Y with CJA, n=429</i>	419 (97.7)	411	18	4.2%	0.089 ^b	0.792 ^c	
<i>R-Y without CJA, n=404</i>	379 (93.8)	377	27	6.7%	0.401 ^b		
<i>PD , n=287</i>	273 (95.1)	274	13	4.5%	0.296 ^b		
<i>PpPD, n=216</i>	205 (94.9)	207	9	4.2%	0.260 ^b		
<i>B-II, n=172</i>	163 (94.8)	152	20	11.6%	<0.001 ^b	0.050 ^c	1.864 (1.001 - 3.471)
<i>Others, n=68</i>	63 (92.6)	63	5	7.4%	0.586 ^b		
State of papilla Vater							
<i>Nonexistent, n=961</i>	925 (96.3)	921	40	4.2%	<0.001 ^b	0.085 ^c	
<i>Naïve, n= 420</i>	385 (91.7)	375	45	10.7%	<0.001 ^b	0.005 ^c	3.268 (1.426 - 7.490)
<i>Post EST or/and EPBD, n =195</i>	192 (98.5)	188	7	3.6%	0.153 ^b		
Indication for DB-ERCP							
<i>CJA stenosis with stones, n=421</i>	416 (98.8)	405	16	3.8%	0.037 ^b	0.349 ^c	
<i>Common bile duct stones, n=385</i>	372 (96.6)	347	38	9.9%	<0.001 ^b	0.203 ^c	
<i>CJA stenosis without stones, n=342</i>	333 (97.4)	323	19	5.6%	0.802 ^b		
<i>Malignant biliary stricture, n=210</i>	196 (93.3)	200	10	4.7%	0.475 ^b		
<i>Pancreatic disease, n=68</i>	57 (83.8)	67	1	1.5%	0.116 ^b		
<i>Others, n=150</i>	128 (85.3)	142	8	5.4%	0.782 ^b		
At the initial procedure, n = 716	654 (91.3)	650	66	9.2%			
At recurrent procedures, n = 860	848 (98.6)	834	26	3.0%	<0.001 ^d		

ASA-PS, American society of anesthesiologists physical status; ASA-PS 3, A patient with a severe systemic disease that is not life-threatening; EST, endoscopic sphincterotomy; EPBD, endoscopic papillary balloon dilation.

^aUsing the unpaired t-test to assess difference in mean values between patients with complication and those without complication.

^bUsing the chi-square test to compare proportion of complications in patients with potential confounding factors and without those factors.

^cMultivariate analysis was performed using logistic regression model after adjusting for confounding factors with p values of <0.1 on univariate analysis.

^dUsing the chi-square test to compare proportion of complications between the initial procedure and recurrent procedures.

Table 4 Management and prognosis of complications

	Treatment, n (%)	Recovery, n (%)	Death, n (%)	The cases of complications directly related death, n (%)	Period of extended hospitalization mean \pm SD, days
Perforation, n=50		46 (92.0)	4 (8)	1 (2)	15.1 \pm 12.6
<i>Type I, n = 5</i>	Surgery, 4 (80) Endoscopy, 1 (20)	3 (60)	2 (40)	0 (0)	12.0 \pm 16.8
<i>Type II, III and IV, n = 45</i>	Endoscopy, 35 (77.8) Conservative management, 9 (20.0) Surgery, 1 (2.2)	43 (95.6)	2 (4.4)	1 (2.2)	15.4 \pm 12.3
Mucosal laceration, n=8	Conservative management, 5 (62.5) Endoscopy, 3 (37.5)	8 (100)	0 (0)	0 (0)	3.1 \pm 3.9
Hemorrhage, n=15	Endoscopy, 11 (73.3) Conservative management, 3 (20.0) Transcatheter arterial embolization (TAE), 1 (6.7)	13 (86.7)	2 (13.3)	1 (6.7)	4.1 \pm 5.9
Pancreatitis, n=9	Conservative management, 8 (88.9) Intensive care, 1 (11.1)	8 (88.9)	1 (11.1)	0 (0)	27.6 \pm 28.9
Respiratory disorder, n=7	Endo-tracheal intubation, 3 (42.9) Insufflation change CO ₂ to room air, 2 (28.6) Emergence from deep sedation, 2 (28.6)	7 (100)	0 (0)	0 (0)	10.0 \pm 12.9
Others, n=3		3 (100)	0 (0)	0 (0)	8.3 \pm 12.7
<i>Subcutaneous emphysema and right pneumothorax, n=1</i>	Drainage of the thoracic cavity, 1 (100)	1 (100)	0 (0)	0 (0)	23 \pm 0
<i>Migration of the guidewire, n=1</i>	Endoscopy, 1 (100)	1 (100)	0 (0)	0 (0)	0 \pm 0
<i>Choledocho-duodeno fistula, n=1</i>	Endoscopy, 1 (100)	1 (100)	0 (0)	0 (0)	2 \pm 0
Total, n=92	Endoscopy, 52 (56.5) Conservative management, 25 (27.2) Surgery, 5 (5.4) Endo-tracheal intubation, 3 (3.3) Insufflation change CO₂ to room air, 2 (2.2) Emergence from deep sedation, 2 (2.2) TAE, 1 (1.1) Intensive care, 1 (1.1) Drainage of the thoracic cavity, 1 (1.1)	85 (92.4)	7 (7.6)	2 (2.2)	12.9 \pm 15.0